A crp mutant gene and its use
By introducing CRP mutant genes, especially the CRP mu9 mutant, into Escherichia coli and Pseudomonas putida, the glucose inhibition effect was resolved, glycolysis and the TCA cycle were activated, glucose utilization and biosynthesis were enhanced, strain growth was promoted, and the level of recombinant expression was increased.
Patent Information
- Application Number
- CN202310234936.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-13
- Publication Date
- 2025-11-25
- Estimated Expiration
- 2043-03-13
AI Technical Summary
In the prior art, Escherichia coli exhibits a glucose inhibition effect in the presence of glucose, leading to a decrease in recombinant expression levels and limited cell growth. In particular, under conditions where glucose is used as a carbon source, commonly used promoters such as lactose promoters are inhibited, affecting biosynthetic capacity.
By introducing CRP mutant genes, especially the CRP mu9 mutant, the glucose inhibition effect is relieved, glycolysis and the TCA cycle are activated, glucose utilization and biosynthesis are enhanced, and strain growth is promoted.
CRP mutant genes, especially the CRP mu9 mutant, significantly relieve glucose inhibition in the presence of glucose, promote strain growth, increase recombinant expression levels, and enhance biosynthetic capacity, particularly in Escherichia coli and Pseudomonas putida.